Education
About Us
Working with TipRanks
Follow Us
Ascelia Pharma AB (SE:ACE)
:ACE
Top Page
Ascelia Pharma AB
(Berlin:ACE)
43Neutral
Ascelia Pharma AB (ACE) vs. S&P 500 (SPY)
Market Cap
kr432.78M
Dividend YieldN/A
Average Volume (3M)746.67K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue GrowthN/A
EPS Growth39.92%
CountrySE
Employees11
SectorHealthcare
Sector Strength60
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.33
Shares Outstanding116,025,530
10 Day Avg. Volume779,264
30 Day Avg. Volume746,674
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ascelia Pharma AB Business Overview & Revenue Model
Company DescriptionAscelia Pharma AB (ACE) is a Swedish specialty pharmaceutical company focused on the development of novel drugs that address unmet medical needs, primarily in the field of oncology. The company's lead product candidate, Orviglance (formerly known as Mangoral), is an oral imaging drug designed to enhance the visualization of liver metastases in patients with impaired kidney function undergoing MRI scans. Ascelia Pharma operates within the pharmaceutical sector, with a commitment to improving diagnostic procedures and treatment options for cancer patients.
How the Company Makes MoneyAscelia Pharma AB generates revenue primarily through the research and development of its proprietary drug candidates. The company aims to monetize its products by progressing them through clinical trials and eventually bringing them to the market upon regulatory approval. Key revenue streams include potential licensing agreements, partnerships with larger pharmaceutical companies, and eventual sales of approved products. Additionally, Ascelia may receive milestone payments and royalties from collaborations with other entities in the pharmaceutical industry. The company's success in securing partnerships and advancing its drug candidates through the development pipeline is crucial to its financial performance.
Ascelia Pharma AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -1.05M | -3.89M | -8.72M | -825.00K | -62.00K | EBIT |
| -110.91M | -147.01M | -137.95M | -93.43M | -36.74M | EBITDA |
| -108.56M | -132.06M | -128.42M | -98.91M | -39.93M | Net Income Common Stockholders |
| -109.29M | -131.22M | -125.90M | -98.70M | -39.91M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 21.86M | 149.56M | 261.60M | 184.69M | 184.23M | Total Assets |
| 87.07M | 218.57M | 333.49M | 255.37M | 250.23M | Total Debt |
| 1.06M | 484.00K | 1.66M | 1.78M | 96.00K | Net Debt |
| -20.80M | -149.07M | -259.94M | -182.91M | -108.42M | Total Liabilities |
| 12.74M | 37.71M | 25.66M | 19.32M | 13.16M | Stockholders Equity |
| 74.33M | 180.86M | 307.83M | 236.06M | 237.06M |
| Cash Flow | Free Cash Flow | |||
| -126.79M | -125.33M | -116.60M | -85.92M | -36.92M | Operating Cash Flow |
| -126.79M | -125.26M | -116.56M | -85.53M | -36.92M | Investing Cash Flow |
| 46.00K | -65.00K | -38.00K | 75.99M | -75.00K | Financing Cash Flow |
| -936.00K | -1.10K | 184.87M | 92.72M | -60.00K |
Ascelia Pharma AB Technical Analysis
Positive
3.06
Price Trends
3.06
Positive
3.06
Positive
2.77
Positive
Market Momentum
0.17
Negative
70.32
Negative
89.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Positive. The current price of 3.06 is above the 20-day moving average (MA) of 3.04, below the 50-day MA of 3.06, and above the 200-day MA of 2.77, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 70.32 is Negative, neither overbought nor oversold. The STOCH value of 89.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ACE.
Ascelia Pharma AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.24B | 3.76 | -41.88% | 2.85% | 17.01% | 0.78% | |
47 Neutral | kr83.03M | ― | -69.81% | ― | -17.91% | 22.80% | |
45 Neutral | €285.14M | ― | -138.15% | ― | -16.76% | 73.00% | |
43 Neutral | kr432.78M | ― | -103.04% | ― | ― | 39.92% | |
43 Neutral | kr261.66M | ― | ― | 5303.85% | 55.59% | ||
36 Underperform | kr305.26M | ― | -42.88% | ― | -100.00% | -17.35% | |
32 Underperform | kr266.40M | ― | -18.77% | ― | ― | 47.39% |
* Healthcare Sector Average
Performance Comparison
SE:ACE
Ascelia Pharma AB
3.73
-3.57
-48.94%
SE:IMMU
Immunicum AB
5.50
-3.50
-38.89%
SE:ISOFOL
Isofol Medical AB
1.82
1.09
150.90%
SE:NXTCL
NextCell Pharma AB
1.22
0.24
24.72%
SE:XBRANE
Xbrane Biopharma AB
0.19
>-0.01
-2.11%
SE:XINT
Xintela AB
0.40
0.14
53.85%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.